APA (7th ed.) Citation

Genhong Li, Jingwei Yao, Zhen Lu, Lian Yu, Qinwei Chen, Lihong Ding, . . . Bing Xu. (2023). Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways. Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Genhong Li, Jingwei Yao, Zhen Lu, Lian Yu, Qinwei Chen, Lihong Ding, Zhihong Fang, Yin Li, and Bing Xu. Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and P38-MAPK Signaling Pathways. Adis, Springer Healthcare, 2023.

MLA (9th ed.) Citation

Genhong Li, et al. Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and P38-MAPK Signaling Pathways. Adis, Springer Healthcare, 2023.